Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.
In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...
Scientists at the Broad Institute and Mass General Brigham have built a generative AI model that creates short DNA segments ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results